comparing different drugs in prevention of post-tympanoplsty nausea and vomiting
Phase 2
- Conditions
- post tympanoplasty nausea and vomiting.Other surgical procedures
- Registration Number
- IRCT201207223915N7
- Lead Sponsor
- Research VICE chancellor of Tabriz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 160
Inclusion Criteria
patients that are candidate for tympanoplasty with ASA class I or II and age 15-60 year.
Exclusion criteria: gastrointestinal diseases, history of treatment with anti emetics or drugs with anti emesis effects at 24 hours before surgery, BMI more than 36.5, pregnant or lactating mothers, opiate abuse, sensitivity reaction to studied drugs.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Post operative nausea and vomiting. Timepoint: every 0-2 hours till 24 hours. Method of measurement: clinical monitoring.
- Secondary Outcome Measures
Name Time Method eed for anti emetic drugs. Timepoint: every 0-2 hours till 24 hours. Method of measurement: Bellville score.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie granisetron and ondansetron efficacy in post-tympanoplasty nausea prevention?
How does granisetron plus dexamethasone compare to ondansetron plus dexamethasone in preventing postoperative nausea and vomiting in otologic surgeries?
Are there specific biomarkers that predict response to serotonin antagonist-based antiemetic regimens in postoperative patients?
What are the potential adverse events associated with granisetron and ondansetron combinations in surgical settings and how are they managed?
What alternative antiemetic combinations or competitor drugs are being evaluated for post-tympanoplasty nausea and vomiting prevention in phase II trials?